Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market
Portfolio Pulse from Vandana Singh
HC Wainwright has initiated coverage on Halozyme Therapeutics Inc (NASDAQ:HALO) with a Buy rating and a price target of $61. The analysts highlight the potential of Halozyme's Enhanze technology in the $41.7 billion U.S. infusion therapy market. They also note the company's commercial product portfolio obtained through the acquisition of Antares Pharma and the development of drug-device combination products.
July 24, 2023 | 6:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics receives a Buy rating from HC Wainwright, with a price target of $61. The potential of its Enhanze technology in the U.S. infusion therapy market is highlighted.
The Buy rating and high price target from HC Wainwright indicate a positive outlook for Halozyme Therapeutics. The potential of its Enhanze technology in the large U.S. infusion therapy market could drive significant growth for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100